Small molecule Bcl-2 inhibitors (ABT-737, ABT-263, and ABT-199 [Venetoclax]) [20, 21] were proposed to combat inherent tumor cell resistance to ITs by studies in cervical adenocarcinoma, pancreatic cancer, and small cell lung cancer [22–24]. Here, BCL2 is linked to small cell lung carcinoma.